
News
GSK: Due to the slowing market penetration of "harder-to-convert unvaccinated consumers," sales of the shingles vaccine in the U.S. decreased by 15% in the third quarter

GSK: Due to the slowing market penetration of "harder-to-convert unvaccinated consumers," sales of the shingles vaccine in the U.S. decreased by 15% in the third quarter